MI-EATON
23.3.2022 11:32:06 CET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group is celebrating 50 years of MLocker® differential production. The mechanical locking differential provides drivers with best-in-class traction without the need for pushbuttons, shift knobs, or other driver intervention, and is applicable to vehicles with both internal combustion engines and electrified vehicles (EVs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005209/en/
“We’re happy to celebrate this important milestone for the MLocker differential, which is built on the success of its predecessor, our popular Posi differential,” said Mark Kramer, business unit director, Torque Control Products, Eaton’s Vehicle Group. “The unique design and proven quality of the MLocker differential have made it the differential of choice for global full-size pickups and sport-utility vehicles, and even a recently launched electrified urban truck in the Asia-Pacific region.”
Driving original equipment innovation
Utilizing a self-contained, automatic engagement mechanism, the MLocker differential engages in low-traction situations when a wheel speed difference (compared to the other rear wheel) of 100 revolutions per minute (RPM) or greater is detected. Automatic locking takes less than a fraction of a second, improving traction and providing the driver with increased safety and confidence when traveling on wet or icy roads, gravel, mud, and dirt. The MLocker differential is also compatible with existing anti-lock brake and vehicle stability systems, which simplifies OEM integration.
During normal driving conditions, the MLocker differential functions as a light-bias, limited-slip differential. When a low-traction situation occurs that causes a wheel speed difference, a flyweight mechanism opens to engage a latching bracket, triggering a self-energizing clutch system until both axles turn at the same speed (full lock), thereby preventing further wheel slip. Unlocking occurs automatically and the differential resumes normal operation.
The MLocker differential has undergone modifications over its long production run, but the foundational design and concept have remained constant.
“Functionally it’s the same design, but we have made a lot of improvements over the years. Our initial concept has weathered the test of time, although it’s been consistently improved to meet the needs of the industry,” said Keith E. Morgensai, an engineering specialist who has been involved in MLocker differential engineering and evolution for more than 40 years.
“It’s deceptively simple, but there is an awful lot of engineering that went into its development,” Morgensai said.
Since launching the MLocker differential, Eaton’s Vehicle Group has continued to add to its differentials portfolio that offers solutions for all user profiles.
Eaton’s complete line of differentials now includes:
- Detroit Locker® differential – A fully automatic locking differential that provides ultimate traction for mild to extreme vehicle applications. It is uniquely engineered to keep both wheels in drive mode, even if one wheel lifts off the ground.
- Detroit Truetrac® differential – A helical-gear performance limited-slip differential that maximizes wheel traction and enhances driving and handling characteristics.
- ELocker® differential – A highly engineered unit that allows maximum driveline flexibility. Users can switch from a fully open to a fully locked axle at the touch of a button. The forged case and four-pinion gears provide added strength and capability.
- InfiniTrac™ differential – An electronically controlled, limited-slip differential that provides optimized vehicle performance at any speed and traction condition.
- Posi® differential – A limited-slip differential that automatically prevents wheel slip before it can start. It easily integrates into most axle designs and is tunable for application requirements.
Eaton also recently announced its Torque control systems business has launched an extensive lineup of specialized differentials for EVs with comparable performance to differentials for traditional internal combustion engine vehicles.
The passenger vehicle market is increasingly transitioning to EVs, and Eaton has the expertise and experience to provide the solution EV manufacturers need.
Eaton’s Traction Control family of differentials can provide improved traction in adverse conditions, such as snow and mud, and improved stability while trailering. As a global supplier, Eaton has extensive knowledge of vehicle dynamics and safety standards, as well as decades of experience working with global automotive manufacturers to integrate differentials into new vehicle platforms, including EVs. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets. By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.
“Our years of experience producing industry-leading differentials allows us to provide our customers with a differential solution to meet their every need,” Kramer said. “The success of the MLocker differential was just the beginning of our journey to become a global supplier of differentials.”
Learn more about Eaton’s complete line of differentials .
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com . Follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005209/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
